Table 1 Baseline characteristics of exceptional responders post ASCT.
Patients (n = 46) | |
|---|---|
Median age at diagnosis, years (IQR) | 57 (50–63) |
Male, n (%) | 18 (39) |
Female, n (%) | 28 (61) |
Myeloma defining event | |
Hypercalcemia, n (%) | 6/43 (14) |
Renal failure, n (%) | 4/40 (10) |
Anemia, n (%) | 18/41 (44) |
Osteolytic bone diseasea, n (%) | 27/43 (63) |
>1 plasmacytoma, n (%) | 4/46 (9) |
Monoclonal protein isotype | |
IgG, n (%) | 30 (65) |
IgA, n (%) | 7 (15) |
IgD, n (%) | 1 (2) |
Light chain, n (%) | 8 (17) |
Median bone marrow plasma cell percentage, n (IQR) | 38 (19–68) |
ISS (n = 35) | |
1 | 19 (54) |
2 | 11 (32) |
3 | 5 (14) |
Cytogenetics | |
t(14;16), n (%) | 1 (2.5) |
Trisomy, n (%) | 7 (17.5) |
t(11;14), n (%) | 2 (5) |
Other isolated abnormalities, n (%) | 5 (12.5) |
No abnormality detected, n (%) | 25 (62.5) |
Induction therapy | |
Thalidomide and dexamethasone, n (%) | 16 (35) |
Vincristine, doxorubicin, dexamethasone, n (%) | 16 (33) |
High-dose dexamethasone, n (%) | 10 (22) |
Melphalan and prednisone, n (%) | 3 (6) |
Bortezomib, thalidomide, dexamethasone, n (%) | 1 (2) |
Unknown, n (%) | 1 (2) |
ASCT conditioning | |
Melphalan 200 mg/m2, n (%) | 33 (72) |
Melphalan 140 mg/m2, n (%) | 4 (9) |
Melphalan 200 mg/m2 + samarium, n (%) | 4 (9) |
Melphalan 200 mg/m2 + total body irradiation, n (%) | 2 (4) |
Melphalan 200 mg/m2 + ibritumomab tiuxetan, n (%) | 1 (2) |
Unknown | 2 (4) |
